tetano
Editor, Senior Moderator
Respirol Case Rep
. 2022 Feb 13;10(3):e0912.
doi: 10.1002/rcr2.912. eCollection 2022 Mar.
Fatal disseminated mucormycosis associated with COVID-19
Tomoya Horiguchi[SUP] 1 [/SUP], Tetsuya Tsukamoto[SUP] 2 [/SUP], Yoko Toyama[SUP] 1 [/SUP], Toshiharu Sasaki[SUP] 3 [/SUP], Tomoyuki Nakamura[SUP] 4 [/SUP], Aki Sakurai[SUP] 3 [/SUP], Naohide Kuriyama[SUP] 4 [/SUP], Satoshi Komatsu[SUP] 4 [/SUP], Yoshiko Shigeyasu[SUP] 1 [/SUP], Takuma Ina[SUP] 1 [/SUP], Eiko Sakurai[SUP] 2 [/SUP], Noriko Nakajima[SUP] 5 [/SUP], Arisa Tsuchimori[SUP] 2 [/SUP], Seiji Yamada[SUP] 2 [/SUP], Tadaki Suzuki[SUP] 5 [/SUP], Kazuyoshi Imaizumi[SUP] 1 [/SUP]
Affiliations
Abstract
Secondary fungal infections are a critical problem that accompany immunosuppressive therapy for severe coronavirus disease 2019 (COVID-19). We report a fatal case of COVID-19 with disseminated mucormycosis diagnosed during autopsy. A 58-year-old man with diabetes was hospitalized for severe COVID-19 and treated with remdesivir, systemic steroids and tocilizumab. Following treatment, he was provided extracorporeal membrane oxygenation support. However, he died of multiple organ failure accompanied by pulmonary and kidney infarction, as revealed by computed tomography. Autopsy revealed that the infarction was caused by thromboangiitis due to mucormycosis in the brain, lungs, heart, liver and kidneys. Therefore, the diagnosis of disseminated mucormycosis was established. Disseminated mucormycosis is a rare complication of COVID-19. Although its early diagnosis is difficult, the disease progresses rapidly. Hence, we propose that immunosuppressive treatment for COVID-19 should be administered with caution considering the risk of developing severe opportunistic infections, such as mucormycosis.
Keywords: COVID‐19; autopsy; mucormycosis; thrombosis.
. 2022 Feb 13;10(3):e0912.
doi: 10.1002/rcr2.912. eCollection 2022 Mar.
Fatal disseminated mucormycosis associated with COVID-19
Tomoya Horiguchi[SUP] 1 [/SUP], Tetsuya Tsukamoto[SUP] 2 [/SUP], Yoko Toyama[SUP] 1 [/SUP], Toshiharu Sasaki[SUP] 3 [/SUP], Tomoyuki Nakamura[SUP] 4 [/SUP], Aki Sakurai[SUP] 3 [/SUP], Naohide Kuriyama[SUP] 4 [/SUP], Satoshi Komatsu[SUP] 4 [/SUP], Yoshiko Shigeyasu[SUP] 1 [/SUP], Takuma Ina[SUP] 1 [/SUP], Eiko Sakurai[SUP] 2 [/SUP], Noriko Nakajima[SUP] 5 [/SUP], Arisa Tsuchimori[SUP] 2 [/SUP], Seiji Yamada[SUP] 2 [/SUP], Tadaki Suzuki[SUP] 5 [/SUP], Kazuyoshi Imaizumi[SUP] 1 [/SUP]
Affiliations
- PMID: 35198214
- PMCID: PMC8841239
- DOI: 10.1002/rcr2.912
Abstract
Secondary fungal infections are a critical problem that accompany immunosuppressive therapy for severe coronavirus disease 2019 (COVID-19). We report a fatal case of COVID-19 with disseminated mucormycosis diagnosed during autopsy. A 58-year-old man with diabetes was hospitalized for severe COVID-19 and treated with remdesivir, systemic steroids and tocilizumab. Following treatment, he was provided extracorporeal membrane oxygenation support. However, he died of multiple organ failure accompanied by pulmonary and kidney infarction, as revealed by computed tomography. Autopsy revealed that the infarction was caused by thromboangiitis due to mucormycosis in the brain, lungs, heart, liver and kidneys. Therefore, the diagnosis of disseminated mucormycosis was established. Disseminated mucormycosis is a rare complication of COVID-19. Although its early diagnosis is difficult, the disease progresses rapidly. Hence, we propose that immunosuppressive treatment for COVID-19 should be administered with caution considering the risk of developing severe opportunistic infections, such as mucormycosis.
Keywords: COVID‐19; autopsy; mucormycosis; thrombosis.